Onkologie. 2020:14(5):240-245 | DOI: 10.36290/xon.2020.081

Perioperative treatment for locally advanced gastric cancer

Michal Eid
Interní hematologická a onkologická klinika FN Brno

The incidence of gastric adenocarcinoma in the Czech Republic is decreasing. However, despite the development of oncology treatment, mortality remains high. In the very early stages, long-term survival can be achieved by endoscopic intervention. Nevertheless, it is possible only in a minority of patients. In stage II and III, radical resection with D2 lymphadenectomy is the main approach of a curative treatment. Even so, the prognosis remains serious due to a high rate of recurrence. Thus, it is now clear that in locally advanced cancers, radical resection alone is not sufficient and perioperative systemic chemotherapy is currently the standard of treatment. This approach leads to the improvement of survival and prognosis. Systemic therapy for locally advanced disease has developed in particular in the last 20 years. The effect of neoadjuvant and adjuvant chemotherapy and chemoradiotherapy has been confirmed in several randomized phase III clinical trials. Currently, research is also focusing on the benefits of target therapy in perioperative setting.

Keywords: gastric cancer, locally advanced, perioperative treatment.

Published: November 19, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Eid M. Perioperative treatment for locally advanced gastric cancer. Onkologie. 2020;14(5):240-245. doi: 10.36290/xon.2020.081.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ÚZIS ČR, NOR ČR 2016, Novotvary 2016, Cancer Incidence 2016 in the Czech Republic
    2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7-30. Go to original source... Go to PubMed...
    3. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2016; 20(1): 1-19. Go to original source... Go to PubMed...
    4. Choi YY, Noh SH, Cheong JH. Evolution of gastric cancer treatment: from the golden age of surgery to an era of precision medicine. Yonsei Med J. 2015; 56(5): 1177-1185. Go to original source... Go to PubMed...
    5. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012; 30(19): 2327-2333. Go to original source... Go to PubMed...
    6. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379(9813): 315-321. Go to original source... Go to PubMed...
    7. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012; 30(3): 268-273. Go to original source... Go to PubMed...
    8. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009; 27(30): 5062-5067. Go to original source... Go to PubMed...
    9. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010; 28(35): 5210-5218. Go to original source... Go to PubMed...
    10. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1): 11-20. Go to original source... Go to PubMed...
    11. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29: 1715-1721. Go to original source... Go to PubMed...
    12. Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013; (5): CD008107. Published 2013 May 31. Go to original source... Go to PubMed...
    13. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393(10184): 1948-1957. Go to original source... Go to PubMed...
    14. Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5): 616-628. Go to original source... Go to PubMed...
    15. Cunningham D, Stenning SP, Smyth EC, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol. 2017; 18(3): 357-370. Go to original source... Go to PubMed...
    16. Leong T, Smithers BM, Haustermans K, et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017; 24(8): 2252-2258. Go to original source... Go to PubMed...
    17. Reynolds JV, Preston SR, O'Neill B, et al. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer. 2017; 17(1): 401. Go to original source... Go to PubMed...
    18. Ji J, Shen L, Li Z, et al. Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: A randomized phase III trial (RESOLVE trial). Annals of Oncology. 2019; 30: v877. Go to original source...
    19. SOX regimen as neoadjuvant chemotherapy for AJCC stage II-III gastric cancer (RESONANCE), ClinicalTrials.gov, (Identifier: NCT01583361).
    20. Aoyama T, Nishikawa K, Fujitani K, et al. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017; 28(8): 1876-1881. Go to original source... Go to PubMed...
    21. Clinicaltrials.gov. A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT04062058.
    22. Clinicaltrials.gov. S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma (Focus). Available from: https://clinicaltrials.gov/ct2/show/NCT01364376.
    23. Clinicaltrials.gov. Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma. (RESOLVE-2). Available from: https://clinicaltrials.gov/ct2/show/NCT03691454.
    24. Kataoka K, Tokunaga M, Mizusawa J, et al. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). Jpn J Clin Oncol. 2015; 45(11): 1082-1086. Go to original source... Go to PubMed...
    25. Terashima M, Kim Y, Yeh T, et al. ATTRACTION-05 (ONO-4538-38/BMS CA209844): a randomized, multicenter, double-blind, placebo - controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer. Ann Oncol 2017; 28(Suppl. 5): v209-268. Go to original source...
    26. Bang YJ, Van Cutsem E, Fuchs CS, et al. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol. 2019; 15(9): 943-952. Go to original source... Go to PubMed...
    27. Petrillo A, Pompella L, Tirino G, et al. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers (Basel). 2019; 11(3): 399. Go to original source... Go to PubMed...
    28. Mirza A, Pritchard S, Welch I. The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas. Int J Surg Oncol. 2013; 2013: 781742. Go to original source... Go to PubMed...
    29. Glatz T, Bronsert P, Schäfer M, et al. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome. Eur J Surg Oncol. 2015; 41(10): 1300-1307. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.